Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

Thitima Kongnakorn,1 James A Sterchele,2 Christopher G Salvador,3 Denis Getsios,4 Mkaya Mwamburi51Evidera, Bangkok, Thailand; 2formerly of Teva Branded Pharmaceutical Products R&D, Inc, Frazer, PA, 3Oncology Market Research, Teva Branded Pharmaceutical Products R&D, Inc, Frazer, PA,...

Full description

Bibliographic Details
Main Authors:	Kongnakorn T, Sterchele JA, Salvador CG, Getsios D, Mwamburi M
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-04-01
Series:	ClinicoEconomics and Outcomes Research
Online Access:	http://www.dovepress.com/economic-implications-of-using-bendamustine-alemtuzumab-or-chlorambuci-a16296

Similar Items

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
by: Francesco Autore, et al.
Published: (2020-06-01)

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
by: Carmen Diana Schweighofer, et al.
Published: (2010-03-01)

Role of bendamustine in the treatment of chronic lymphocytic leukemia
by: Saad Jamshed, et al.
Published: (2009-03-01)

The expanding role of bendamustine in chronic lymphocytic leukemia
by: Nair KS, et al.
Published: (2015-07-01)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
by: Sara E. F. Kost, et al.
Published: (2019-10-01)

Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
by: Casado LF, et al.
Published: (2016-09-01)

IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
by: M. N Khorobrykh, et al.
Published: (2014-07-01)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
by: Marco Montillo, et al.
Published: (2008-03-01)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

Efficacy of combination of rituximab therapy with chlorambucil plus prednisolone (R-LP) Protocol as treatment line in chronic lymphocytic leukemia patients
by: Waseem F Al Tameemi
Published: (2015-01-01)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
by: Steven E. Coutre, et al.
Published: (2018-06-01)

Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study
by: E A Stadnik, et al.
Published: (2017-07-01)

Chlorambucil effect on B lymphocites in the peripheral blood of patients with chronic lymphocytic leukemia: Cell ultrastructure investigation
by: Brajušković Goran R., et al.
Published: (2003-01-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
by: Martina Bogeljić Patekar, et al.
Published: (2018-01-01)

Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia
by: Hang Gao, et al.
Published: (2020-01-01)

Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro
by: Ewelina Ziolkowska, et al.
Published: (2014-12-01)

CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.
by: Luca Laurenti, et al.
Published: (2013-05-01)

Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
by: William Y. K. Hwang, et al.
Published: (2009-01-01)

Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
by: Shinya Rai, et al.
Published: (2018-09-01)

Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature
by: Housam Haddad, et al.
Published: (2014-12-01)

Glutathione and glutathione S-transferases in chlorambucil resistant mouse cell lines
by: Yang, Wen Z.
Published: (2013)

Glutathione and glutathione S-transferases in chlorambucil resistant mouse cell lines
by: Yang, Wen Z.
Published: (2013)

The absorption and disposition of melphalan and chlorambucil
by: Adair, Colin George
Published: (1986)

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
by: Antonio Cuneo, et al.
Published: (2020-11-01)

Chlorambucil-Iron Oxide Nanoparticles as a Drug Delivery System for Leukemia Cancer Cells
by: Hussein-Al-Ali SH, et al.
Published: (2021-09-01)

Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility
by: James E, et al.
Published: (2021-03-01)

Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia
by: Jan J. Meeuse, et al.
Published: (2007-12-01)

HPLC-UV and GC-MS Methods for Determination of Chlorambucil and Valproic Acid in Plasma for Further Exploring a New Combined Therapy of Chronic Lymphocytic Leukemia
by: Katarzyna Lipska, et al.
Published: (2021-05-01)

Chlorambucil-Induced Acute Interstitial Pneumonitis
by: Hammad Shafqat, et al.
Published: (2014-01-01)

NO/HNO Releasing Derivatives of Chlorambucil and Aspirin
by: Giridharan, Kavya Sindhu
Published: (2012)

Effect of Alemtuzumab on Intestinal Intraepithelial Lymphocytes and Intestinal Barrier Function in Cynomolgus Model
by: Lin-Lin Qu, et al.
Published: (2015-01-01)

Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia
by: YuV Mirolyubova, et al.
Published: (2018-04-01)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
by: Havrdova E, et al.
Published: (2017-10-01)

The molecular mechanism of action of Bendamustine
by: Bagnobianchi, A.
Published: (2015)

The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy
by: Sanja Stanisic, et al.
Published: (2019-04-01)

A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes
by: A. G. Vakrakou, et al.
Published: (2018-10-01)

Alemtuzumab in the up-front setting
by: Matthew Kaufman, et al.
Published: (2008-04-01)